Podcasts about co inventor

Send us Fan MailEvery once in a while, a simple question changes medicine forever.For decades, chronic and traumatic wounds were among the most frustrating problems in healthcare. Doctors could clean wounds, dress wounds, and hope for healing - but many patients remained trapped in cycles of infection, inflammation, and failed recovery.Then came one deceptively simple idea:  What happens if you apply vacuum?That question led to the creation of Vacuum Assisted Closure - better known worldwide as V.A.C.® Therapy ( https://www.solventum.com/en-us/home/medical/advanced-wound-care/negative-pressure-wound-therapy/vac-therapy/ ) - developed by plastic surgeon Dr. Louis Argenta and biomedical engineer Dr. Michael Morykwas ( https://www.renovoconcepts.com/michaelmorykwasbio ).The technology transformed wound care by using controlled negative pressure to remove fluid, stimulate blood flow, encourage tissue growth, and accelerate healing. What began as a bold experiment evolved into one of the most important advances in modern medicine, helping more than 20 million patients worldwide - from burn victims and diabetic patients to wounded soldiers returning from Iraq and Afghanistan.For this groundbreaking work, Drs. Argenta and Morykwas were inducted into the National Inventors Hall of Fame ( https://www.invent.org/inductees/michael-morykwas ).Today, we're joined by Dr. Michael Morykwas - bioengineer, inventor, scientist, and lifelong tinkerer - to explore the origins of this revolutionary technology, the science behind mechanobiology and wound healing, the long road from prototype to global adoption, and what the future of regenerative medicine may look like next.Photo Credit - National Inventors Hall of Fame #MichaelMorykwas #VACtherapy #WoundHealing #RegenerativeMedicine #Mechanobiology #BiomedicalEngineering #MedicalInnovation #NegativePressureWoundTherapy #TissueEngineering #HealthcareInnovation #PlasticSurgery #Bioengineering #MedicalBreakthrough #Inventor #NationalInventorsHallOfFame #RegenerativeScience #MilitaryMedicine #FutureOfMedicine #MedTech #SciencePodcast #InnovationPodcast #HealthcareTechnology #StemCells #WoundCare #MedicalScienceSupport the show

The Co-Inventor of Tor on Why Your NHI Strategy Is Already BehindMost organizations have spent the last 20 years getting really good at human identity. 2FA. Biometrics. Face ID. Ephemeral tokens. They did the work. And the whole time, they were quietly pushing every ounce of that compressed risk onto the non-human side of the house.Service accounts with username and password. API keys that never rotate. Credentials hardcoded in pipelines. Long-lived tokens that were supposed to be temporary.Eventually is here.In this episode, David Lee sits down with David Goldschlag, CEO and co-founder of Aembit and one of the original inventors of onion routing — the technology that became Tor. With 20+ years building security companies, David G brings a perspective on non-human identity and AI agent security that very few people in this industry can match.They get into why NHI is not a new problem but a neglected one, what it actually means to build a zero trust framework for AI agents, the concept of blended identity and why your existing IAM stack is only part of the answer, why workforce agents and customer agents are fundamentally different and why treating them the same is a mistake, and why data is still the new oil and why that matters more now than ever.If your org is spinning up agents and hasn't had a real strategic conversation about what those agents can access, who they're acting on behalf of, and what happens when something goes wrong, this episode is exactly where you need to start.Topics CoveredThe origins of Tor and why onion routing still matters 30 years laterHow Aembit went from "Okta for workloads" to purpose-built AI agent identityThe three types of agents: autonomous, workforce, and customer-facingBlended identity and blended policy in practiceWhy ephemeral credentials are non-negotiable for agent accessZero trust for AI: the three pillars (identity, prompt security, data security)Non-repudiation in the age of agentic AIWhy vibe coders are making the NHI problem exponentially harderData security as the ultimate endpoint for every breach scenarioStay ConnectedSubscribe to the Identity Jedi newsletter at theidentityjedi.comFollow on LinkedIn, YouTube, and SpotifyRate, review, and share if this episode hit different

What if the technology that could save humanity…could also predict its end? In this episode of Mayim Bialik's Breakdown, Michio Kaku — legendary cofounder of string field theory and author of Quantum Supremacy — breaks down the quantum revolution that's about to change everything. What is quantum computing, really? Dr. Kaku explains its evolution from wild theory to world-altering reality — and how it could soon solve problems today's supercomputers can't even touch. But that's just the beginning. He reveals how quantum computing could: - Extend human longevity and transform medicine - Track dangerous asteroids before they strike - Accelerate the search for extraterrestrial life - Predict possible planetary catastrophes - Help us study parallel universes Are black holes actually gateways to interstellar travel? Dr. Kaku explains the shocking physics that suggests they might not just destroy matter, but connect distant regions of space-time. Are we alone in the universe? He explains why he believes we are not, and how string theory may one day prove the existence of a multiverse. Artificial Intelligence: Humanity's Greatest Tool — or Its Biggest Threat? Dr. Kaku shares why advancing AI deeply concerns him, why fighting AI may be the wrong strategy, and why he believes we may eventually need to merge with it instead. Could AI and robots become our partners in space exploration? Will artificial intelligence ever achieve consciousness? What would physically merging with technology actually look like? And what safeguards must we build before that future arrives? Plus: Why he predicts we may see more “3I/ATLAS”-type interstellar comets entering our solar system, and what that means for Earth. From quantum supremacy to the multiverse…from AI-human integration to black holes as cosmic gateways…this conversation explores the future of humanity at its most extreme edge. The future isn't science fiction. It's already unfolding. Dr. Michio Kaku's book, Quantum Supremacy: How the Quantum Computer Revolution Will Change Everything: ⁠https://www.penguinrandomhouse.com/books/697040/quantum-supremacy-by-michio-kaku/⁠ Follow us on Substack for Exclusive Bonus Content: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bialikbreakdown.substack.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠BialikBreakdown.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube.com/mayimbialik⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What if the technology that could save humanity…could also predict its end? In this episode of Mayim Bialik's Breakdown, Michio Kaku — legendary cofounder of string field theory and author of Quantum Supremacy — breaks down the quantum revolution that's about to change everything. What is quantum computing, really? Dr. Kaku explains its evolution from wild theory to world-altering reality — and how it could soon solve problems today's supercomputers can't even touch. But that's just the beginning. He reveals how quantum computing could: - Extend human longevity and transform medicine - Track dangerous asteroids before they strike - Accelerate the search for extraterrestrial life - Predict possible planetary catastrophes - Help us study parallel universes Are black holes actually gateways to interstellar travel? Dr. Kaku explains the shocking physics that suggests they might not just destroy matter, but connect distant regions of space-time. Are we alone in the universe? He explains why he believes we are not, and how string theory may one day prove the existence of a multiverse. Artificial Intelligence: Humanity's Greatest Tool — or Its Biggest Threat? Dr. Kaku shares why advancing AI deeply concerns him, why fighting AI may be the wrong strategy, and why he believes we may eventually need to merge with it instead. Could AI and robots become our partners in space exploration? Will artificial intelligence ever achieve consciousness? What would physically merging with technology actually look like? And what safeguards must we build before that future arrives? Plus: Why he predicts we may see more “3I/ATLAS”-type interstellar comets entering our solar system, and what that means for Earth. From quantum supremacy to the multiverse…from AI-human integration to black holes as cosmic gateways…this conversation explores the future of humanity at its most extreme edge. The future isn't science fiction. It's already unfolding. Dr. Michio Kaku's book, Quantum Supremacy: How the Quantum Computer Revolution Will Change Everything: ⁠https://www.penguinrandomhouse.com/books/697040/quantum-supremacy-by-michio-kaku/⁠ Follow us on Substack for Exclusive Bonus Content: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bialikbreakdown.substack.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠BialikBreakdown.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube.com/mayimbialik⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

What if the technology that could save humanity…could also predict its end? In this episode of Mayim Bialik's Breakdown, Michio Kaku — legendary cofounder of string field theory and author of Quantum Supremacy — breaks down the quantum revolution that's about to change everything. What is quantum computing, really? Dr. Kaku explains its evolution from wild theory to world-altering reality — and how it could soon solve problems today's supercomputers can't even touch. But that's just the beginning. He reveals how quantum computing could: - Extend human longevity and transform medicine - Track dangerous asteroids before they strike - Accelerate the search for extraterrestrial life - Predict possible planetary catastrophes - Help us study parallel universes Are black holes actually gateways to interstellar travel? Dr. Kaku explains the shocking physics that suggests they might not just destroy matter, but connect distant regions of space-time. Are we alone in the universe? He explains why he believes we are not, and how string theory may one day prove the existence of a multiverse. Artificial Intelligence: Humanity's Greatest Tool — or Its Biggest Threat? Dr. Kaku shares why advancing AI deeply concerns him, why fighting AI may be the wrong strategy, and why he believes we may eventually need to merge with it instead. Could AI and robots become our partners in space exploration? Will artificial intelligence ever achieve consciousness? What would physically merging with technology actually look like? And what safeguards must we build before that future arrives? Plus: Why he predicts we may see more “3I/ATLAS”-type interstellar comets entering our solar system, and what that means for Earth. From quantum supremacy to the multiverse…from AI-human integration to black holes as cosmic gateways…this conversation explores the future of humanity at its most extreme edge. The future isn't science fiction. It's already unfolding. Check Out Odoo, The all-in-one platform to manage your business by visiting https://www.odoo.com/r/J4l Make a change this spring with a scientific approach to clean air. Visit http://rabbitair.com/ or call their 24/7 consultants today. Get 20% off all IQ Bar products - plus free shipping by texting BREAKDOWN to 64000. Dr. Michio Kaku's book, Quantum Supremacy: How the Quantum Computer Revolution Will Change Everything: https://www.penguinrandomhouse.com/books/697040/quantum-supremacy-by-michio-kaku/ Follow us on Substack for Exclusive Bonus Content: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bialikbreakdown.substack.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠BialikBreakdown.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube.com/mayimbialik⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What if the technology that could save humanity…could also predict its end? In this episode of Mayim Bialik's Breakdown, Michio Kaku — legendary cofounder of string field theory and author of Quantum Supremacy — breaks down the quantum revolution that's about to change everything. What is quantum computing, really? Dr. Kaku explains its evolution from wild theory to world-altering reality — and how it could soon solve problems today's supercomputers can't even touch. But that's just the beginning. He reveals how quantum computing could: - Extend human longevity and transform medicine - Track dangerous asteroids before they strike - Accelerate the search for extraterrestrial life - Predict possible planetary catastrophes - Help us study parallel universes Are black holes actually gateways to interstellar travel? Dr. Kaku explains the shocking physics that suggests they might not just destroy matter, but connect distant regions of space-time. Are we alone in the universe? He explains why he believes we are not, and how string theory may one day prove the existence of a multiverse. Artificial Intelligence: Humanity's Greatest Tool — or Its Biggest Threat? Dr. Kaku shares why advancing AI deeply concerns him, why fighting AI may be the wrong strategy, and why he believes we may eventually need to merge with it instead. Could AI and robots become our partners in space exploration? Will artificial intelligence ever achieve consciousness? What would physically merging with technology actually look like? And what safeguards must we build before that future arrives? Plus: Why he predicts we may see more “3I/ATLAS”-type interstellar comets entering our solar system, and what that means for Earth. From quantum supremacy to the multiverse…from AI-human integration to black holes as cosmic gateways…this conversation explores the future of humanity at its most extreme edge. The future isn't science fiction. It's already unfolding. Check Out Odoo, The all-in-one platform to manage your business by visiting https://www.odoo.com/r/J4l Make a change this spring with a scientific approach to clean air. Visit http://rabbitair.com/ or call their 24/7 consultants today. Get 20% off all IQ Bar products - plus free shipping by texting BREAKDOWN to 64000. Dr. Michio Kaku's book, Quantum Supremacy: How the Quantum Computer Revolution Will Change Everything: https://www.penguinrandomhouse.com/books/697040/quantum-supremacy-by-michio-kaku/ Follow us on Substack for Exclusive Bonus Content: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bialikbreakdown.substack.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠BialikBreakdown.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube.com/mayimbialik⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

You built something together, the invention is real, the patent application is ready… and then everything grinds to a halt because your co-inventor suddenly won't sign. What happens now? Is the patent dead? Can they hold the invention hostage? In this episode, we talk through what the law actually requires when an inventor refuses to cooperate, what options still exist, and why this situation is far more common than most inventors realize. If you've ever worried that a falling-out could derail your patent, this episode might save you a lot of panic—and a lot of time.   Connect with Adam Diament E-mail: adiament@nolanheimann.com   Website: https://www.nolanheimann.com/legal-team/adam-diament   Phone/Text: (424)281-0162   YouTube: https://www.youtube.com/channel/UC5cTADZzJfPoyQMjnW-rtRw Instagram: https://www.instagram.com/trademarkpatentlaw/   LinkedIn: https://www.linkedin.com/in/adam-diament-j-d-ph-d-180a005/   Amazon Book Page: https://www.amazon.com/stores/author/B005SV2RZC/allbooks?ingress=0&visitId=831aff71-513b-4158-ad73-386ede491e93

If you grew up watching MTV… if you've ever listened to a podcast… or if you've simply existed on the internet in the last 20 years… you've been impacted by today's guest, whether you knew it or not.Adam Curry — former MTV icon, media pioneer, and co-inventor of podcasting — joins me for a conversation that honestly feels like a movie. Most people know him as the Podfather… but very few know the plot twist that happened at age 58, when God interrupted his life and everything changed.In today's episode, Adam opens up about:✨ His wild behind-the-scenes years at MTV✨ How the early days of the internet and podcasting REALLY unfolded✨ The moment he realized the life he built wasn't enough✨ His unexpected, late-life encounter with Jesus✨ What it looked like to learn hearing God's voice for the first time✨ The surprising ways God had been chasing him for decades✨ The spiritual battle inside the media world (and what Christians miss)✨ How God repurposed his ENTIRE career for Kingdom impactAnd then… we talk about Godcaster — Adam's bold new mission to raise up 1,000 Christian voices and build a future where churches, ministries, and everyday believers become the broadcasters of hope in their communities.This conversation is raw, fascinating, tender, and honestly one of the most hope-stirring testimonies you'll hear this year. If you've ever wondered:

With sign-stealing scandals shaking Major League Baseball, the game needed a solution. Enter PitchCom, the cutting-edge communication technology that's changing the way baseball is played.In this episode of The TechEd Podcast, host Matt Kirchner sits down with John Hankins, co-inventor and owner of PitchCom, to unpack the surprising origins of the technology (it was inspired by John's stage mentalism experience!), the innovative and unhackable tech that comprises the PitchCom system, and why it has completely changed the game of baseball. Beyond baseball, PitchCom is a case study in applied technology—how engineering, wireless communication, encryption, and even sound design can be used in unexpected ways. The lesson for educators? What your students learn in the technical education classroom—electronics, software, mechanics, and problem-solving—can lead to groundbreaking inventions in any arena.Listen to learn:How stage mentalism, sound engineering, and encryption tech came together to create PitchComHow PitchCom reduced wild pitches to the lowest levels in MLB history and sped up game play by cutting down time lost to sign-callingWhy PitchCom's encryption is so secure that it's mathematically impossible for teams to hack—more secure than the number of atoms in the universeHow engineering students can apply their skills in creative industries—from sports tech to entertainment and beyondWhy college baseball, the Canadian Football League, and even scuba diving are exploring this technologyWhat future inventors need to know about turning ideas into patented, market-ready productsIf you teach technical education or have students interested in technology, this episode is a must-listen. The next big innovation could come from your classroom!3 Big Takeaways from this Episode:1. Innovation thrives in times of urgency and challenge.PitchCom wasn't just a cool idea—it was a solution to a crisis in baseball. The Houston Astros' sign-stealing scandal created an undeniable need for secure communication, and John Hankins applied existing technology in a new way to fill that gap. Great inventions don't start with ideas—they start with problems.2. True innovation comes from blending different disciplines.John's background as an engineer, patent attorney, and stage mentalist gave him a unique perspective on communication and encryption. Whether it's combining sports and tech, or magic and engineering, the biggest breakthroughs come from crossing industry boundaries and thinking outside traditional silos.3. Data is the future of every industry.PitchCom started as a tool to prevent sign-stealing, but now it's unlocking new levels of player performance data—tracking pitch accuracy, command, and strategy in real time. From sports to manufacturing to education, those who understand and leverage real-time data insights will lead the future.Resources in this Episode:To learn more about PitchCom's technology, visit: pitchcom.comWe want to hear from you! Send us a text message.Instagram - Facebook - YouTube - TikTok - Twitter - LinkedIn

Join Mike Paciello, Chief Accessibility Officer at AudioEye, and Bryce Johnson, Principal Research Accessibility and Inclusive Design at Microsoft and Co-Inventor of the Xbox adaptive controller, in the latest episode of HearSay. Mike and Bryce discuss accessibility in online gaming and the incredible work that's gone into making the industry more accessible to individuals with disabilities. They also discuss how organizations can make their designs more inclusive using data and involving the disability community as much as possible.——View transcript: https://aeurl.xyz/hearsay-podcast-with-bryce-johnsonHearSay is produced by Sojin Rank, Mike Barton, Mariella Paulino, and Missy Jensen. Edited by Alex Dorrier.HearSay is a podcast focusing on the advocates, heroes, and leaders making the web more accessible. We're interviewing these change makers to hear what they have to say, to set the record straight, and offer their perspectives on how we can all work to make the web accessible to all.

Peter Voss is the visionary founder and CEO of Aigo.ai, a pioneering company at the forefront of conversational AI and natural language processing. Over the past 15 years, Peter and his team have perfected a highly intelligent, hyper-personalized chatbot designed for enterprise customers. In 2009, Peter founded SmartAction.ai, which developed the first AI-based contact center technology. Beyond his entrepreneurial endeavors, Peter is an engineer, inventor, and AI pioneer who writes and presents on philosophical topics such as rational ethics, free will, and artificial minds. He is also deeply involved in futurism and radical life extension.In this episode, we discuss:Peter Voss's Journey: From an electronics engineer to creating a successful software company, and his deep dive into the nature of intelligence and AI.Defining AGI: What Artificial General Intelligence (AGI) means to Peter, and how we will recognize its achievement.Cognitive Skills Gap: The differences between current AI technologies like large language models (LLMs) and true cognitive skills required for AGI.Path to AGI: The limitations of deep learning and LLMs, and why cognitive AI is the necessary path towards achieving AGI.Human Interaction and Intelligence: The importance of real-time learning, metacognition, and minimal sensory input in developing AGI.Ethics and Responsibility in AI: The philosophical and practical considerations of developing AGI, including the ethical implications and societal benefits.ResourceConnect with Peter AI fun fact articleAn episode you might like about the future of corporate VC

Dave is one of the original innovators in what is now known as 'dirty electricity' assessment and remediation.  We explore the origins of this space, effects on rats and people with specific information on most harmful frequencies, a little of what Dave learned from working with scientists in Russia, decreased use of asthma medicine and reduced insulin use, how to deploy in your own home, how to create your own whole-house DE filter, and my fantasy next gen DE filtration product.Support the Show.Support this podcast here: https://www.emfremedy.com/donate/Keith Cutter is President of EMF Remedy LLChttps://www.emfremedy.com/YouTube Channel: https://www.youtube.com/channel/UCp8jc5qb0kzFhMs4vtgmNlgKeith's SubstackThe EMF Remedy Podcast is a production of EMF Remedy LLCHelping you helping you reduce exposure to harmful man-made electromagnetic radiation in your home.

The Three Dimensions of Customer Value CreationRob Markey ought to know a thing or two about customer loyalty. Rob was a CX expert and thought leader at Bain long before he and his colleague Fred Reichheld introduced Net Promoter to the world. He is a leader in Bain's Customer Customer Strategy and Marketing practice and the co-author of The Ultimate Question 2.0 with Fred Reichheld.This episode was originally intended as a deep dive on customer loyalty through the customer lifecycle for my Michigan State University Master's students but it was just too good to not share in an episode.  As usual, Rob brings insights and wisdom to empower anyone interested in creating value for their customers starting with the three dimensions of value according Bain uses in their approach with clients. Also included in this episode:

Fresh from his exciting win of the Lasker Award - often dubbed the American Nobel Prize - Professor David Huang (USA) - the inventor of optical coherence tomography (OCT) - joins Prof Pearse Keane (UK) and Tunde Peto (Hungary/UK) to talk about how he and colleagues developed the technology and about the impact it has had on retinal medicine

Brian speaks with a team from NervGen Pharma. It is a Canadian start up trying to solve spinal cord injury. He is joined by:Dr. Harold Punnett, Co-FounderMike Kelly, President & CEO,Dr Jerry Silver, Co-Inventor & Scientific Advisor. NervGen Pharma's highly anticipated Phase II study of the potentially breakthrough drug NVG-291 in individuals with Spinal Cord Injury (SCI) isn't just “another clinical trial.” This drug has the potential to be transformational to the over 300,000 individuals who suddenly and without preparation or warning, suffered a life-altering traumatic injury resulting in either a significant disability or paralysis that has become “permanent” and with little to no hope for recovery or improvement.

Get ready to be inspired by our next guest, Alia Rahman, a true powerhouse in the BioTech industry! With a remarkable ability to multitask, Alia effortlessly juggles multiple roles, establishing herself as a force to be reckoned with. As the Co-founder & CEO of Amplexd Therapeutics and the Co-Inventor of Two Non-Invasive Cervical Dysplasia Treatments, Alia is on a mission to revolutionize women's health globally.Driven by her personal journey with dysplasia, Alia embodies the spirit of a patient-scientist, advocate, and innovator. Her relentless pursuit of developing non-invasive dysplasia treatments underscores her commitment to enhancing patient experiences, ensuring accessibility, and maximizing effectiveness. Alia's impressive background as an engineer, award-winning entrepreneur, keynote speaker, product developer, and executive leadership coach speaks volumes about her expertise and dedication. Her passion for advancing the BioTech and Cancer care space is truly inspiring, and her impact is bound to be far-reaching.Join us on this engaging podcast episode as Alia shares her invaluable insights into the BioTech industry. Discover her personal aspirations, delve into the groundbreaking work at Amplexd Therapeutics, and get a glimpse into her day-to-day life. Don't miss the opportunity to hear her perspectives on women's health, innovation, and the future of BioTech.And for a touch of fun, Alia will also take on our FemTech Five rapid-fire game, giving us a peek into her lighter side! Tune in and be inspired by Alia Rahman's remarkable journey and vision for a healthier future! DISCLAIMER: The content in the podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your doctor or qualified healthcare provider. Connect with FemTech India Website: https://www.femtechindia.com/Linkedin: https://www.linkedin.com/company/femtechindiaorg/Twitter : https://twitter.com/Femtech_india?t=HIyteldoOxSIAXwsEXYv4w&s=09Instagram: https://www.instagram.com/femtechindia_podcast?igsh=bzd4a2ZheXc0cm1sYoutube : https://www.youtube.com/@TheFemTechIndiaPodcast Connect with Navneet Linkedin : https://www.linkedin.com/in/navneet-kaur-80109b227/Twitter : https://twitter.com/Navneet_Kaurrrr

Drs. Vamsi Velcheti, Taofeek Owonikoko, and Janakiraman Subramanian discuss their experiences navigating the cancer drug shortage in the United States, the impact on patients and clinical trial enrollment, lessons learned, and proactive strategies to mitigate future crises. TRANSCRIPT  Dr. Vamsi Velcheti: Hello, I'm Dr. Vamsi Velcheti, your guest host for the ASCO Daily News Podcast today. I'm a professor of medicine and director of thoracic oncology at the Perlmutter Cancer Center at NYU Langone. On today's episode, we'll be discussing the impact of the shortage of cancer chemotherapy drugs across the United States. This has been affecting several thousands of patients with adult and pediatric cancers and hampering enrollment in clinical trials. Among the shortages are very commonly used drugs like cisplatin, carboplatin, methotrexate, and fludarabine. Some of these shortages have persisted since the time of the pandemic in 2020.   So today, to discuss this really troubling scenario, I have two outstanding colleagues, Dr. Janakiraman Subramanian, the director of thoracic oncology at Inova Schar Cancer Institute in Virginia, and Dr. Taofeek Owonikoko, a professor of medicine and the chief of the Division of Hematology and Oncology at the University of Pittsburgh Hillman Cancer Center in Pittsburgh.   Our full disclosures are available in the transcript of this episode, and disclosures relating to all episodes of the podcast are available at asco.org/DNpod.  So, a recent survey by the NCCN found that 90% of the nation's largest cancer centers have experienced a shortage in carboplatin, and 70% of the centers have reported a shortage in cisplatin. These are platinum-based chemotherapies we use frequently in patients with cancer, and these are often curative intent treatments for several cancers, and these are used in several tumor types, both solid tumors and hematologic malignancies. So, the scale of the problem is immense.   Dr. Owonikoko, I'd like to hear your take on this situation and how are you dealing with this at the UPMC Cancer Center.  Dr. Taofeek Owonikoko: Yeah, thank you, Dr. Velcheti, and happy to be part of this panel. As you rightly surmised, the chemotherapy drug shortage is what we've all experienced across the length and breadth of the United States. Our cancer center here in Pittsburgh is not an exception. We've had to be proactive as well as think outside the box to be able to manage the challenge. Just like every other cancer center across the country, maybe to varying degrees, we've had to look at patients in need of chemotherapy with these standard-of-care agents such as cisplatin or carboplatin, and to some degree docetaxel, during this past episode of drug shortage that we all went through. And while we did not have to, fortunately, cancel any patient treatment, we all went through it with bated breath; not sure of where the next batch of chemotherapy drugs will come through, but I would say in the past couple of weeks, we've actually seen some improvement in drug availability.   But before then, we've had to have contingency plans where, on a weekly basis, we review our patient list and the drug regimens that they're going to need, and must make sure that we have enough drug on hand for those patients. And in situations where we thought we might not have enough drug; we also had a plan to use alternative regimens. We were proactive in having guiding principles that are consistent with ASCO's recommendations in terms of quality care delivery for cancer patients. So, I'm sure that this is more or less the same approach adopted by other leading cancer centers across the country.   Dr. Vamsi Velcheti: Thank you, Dr. Owonikoko. And Dr. Subramanian, you're in a community setting, a large cancer center that serves a lot of patients in the state of Virginia. So, what is the scale of the problem at your institution and how are you handling it?   Dr. Janakiraman Subramanian: First of all, Dr. Velcheti, thanks for having me here on this panel. And as you rightly said, this is a significant problem, and it is across the country like Dr. Owonikoko said. And as medical oncologists, we are not always thinking of drug shortages. Our focus is on taking care of our patients. So, this is one more issue that we need to keep in mind now as we manage our patients with cancer. When this shortage started, the biggest problem, as you know, was when we became aware of this was primarily in cisplatin and we had some of our patients who were getting curative treatment and we had to make a decision - can they get cisplatin or can they get carboplatin. And one of the things we did was to have an ethics committee that will review each patient that is being planned to receive cisplatin-based chemotherapy and come to a decision on how best we can support them.   The template for some of this was based upon some of the triage mechanisms we used during COVID, as well as the ASCO guideline document for managing this chemotherapy shortage, which was one of the blueprints we used. And they have reviewed all cases, all patients that are being planned for cisplatin or carboplatin for that matter, and we come to a decision based on that. And we also have another committee that constantly monitors drug availability on a weekly basis and tries to forecast where the next problem would be as we take care of our patients.   And particularly as a lung cancer doctor, we've had situations where we had to use carboplatin instead of cisplatin and even we also have carboplatin shortage. And so, the committee usually approves two cycles at a time, but thankfully so far we have not had a situation where we could not offer our patients the chemotherapy treatment. But we are very carefully monitoring the situation, hoping that this will improve.   The other aspect of the shortage has been in 5FU. A lot of our GI colleagues; I treat esophageal cancer patients as well, where we've had to forego the bolus 5FU and have a 10% reduction on all 5FU infusions. And we've been using some of that dose reduction to ensure that we can have 5FU available for all our patients. And that's how we've been trying to manage this shortage situation here at Inova Schar.   Dr. Vamsi Velcheti: Dr. Subramanian and Dr. Owonikoko, we are oncologists, we are treating patients, and the toughest part really is telling a patient that we don't have access to certain drugs and we have to switch treatments to perhaps another treatment regimen that may be suboptimal. And it's always a very anxiety-provoking discussion, and especially for patients with metastatic cancer, they're already under a lot of stress and it's a really difficult conversation. How do you handle that, Dr. Owonikoko?  Dr. Taofeek Owonikoko: That's a conversation we all hope we don't have to have. And fortunately, with this current crisis, I've actually not had such misfortune of having to inform a patient that we don't have drugs to treat them or that we have to switch to something inferior. But conceptually, it's possible that could have happened and that would have been very difficult. But the one thing that we did, though, as part of our mitigation strategy was actually to inform the patient ahead of time because the way we handled this was to look at our inventory on a week-by-week basis. And if there are patients where we felt maybe they will be coming in towards the end of the week and we may not have enough drugs for them, to let them know the possibility exists that we might have to switch them to something different. While we did not have to do that for any patient, yes, there are patients that we had to give that heads up to, to say, “We're having this shortage. We're doing everything we can to make sure it's available. But just in case it's not available…” I think what is most important for most patients is to be aware of that decision ahead of time, to be able to process it, and to be transparent.   The other challenge that we face was, if you have to choose between patients, what should be your guiding principles as to who gets the drug and who doesn't get it? I think it's very easy for all of us to say, “Oh, if it's curative intent, we do it. If it's not curative intent, we don't do it.” It's a little more complicated than that because if we put the equity hat on, curative intent doesn't actually mean that that life is more valuable than somebody who cannot be cured. And this is where really, I think having people with expertise in ethics of care delivery and disaster management will be very important for us to proactively anticipate that, should this become a recurrent problem in the future that we actually have a well-vetted approach, just like we did during COVID where you have to ration resources that we have those people with expertise to help us as oncologists because not all of us, at least personally I can speak for myself, that is not my area of expertise and comfort.  Dr. Vamsi Velcheti: Excellent points. Dr. Subramanian, anything to add?  Dr. Janakiraman Subramanian: Oh, absolutely. I echo what Dr. Owonikoko said. These are conversations that we would like to hopefully never have with our patients. But this is a crisis that we are facing now. And personally, I can tell you two situations where we ran into this problem. But overall, though, we never had to stop a treatment or cancel a treatment for our patient. In the first situation, we had a young man with a rare germ cell tumor in the hospital for whom cisplatin was key. He was already in the ICU and sometimes the treatment start dates are not perfect, unlike what we do in the outpatient setting, depending on how well he's doing or the treatment start dates might move by a day or so. So we basically had to hold a certain dose of cisplatin for him.   This brings the next question, which is how do we decide who gets cisplatin versus who can go for an alternative option? And I think Dr. Owonikoko made a great point where, just because it is a curative disease does not mean their life is more valuable. This is where I think trying to make that decision at an individual level, as an individual treating physician can be extremely hard. And that's why at our institution we have this ethics committee where we have oncologists, pharmacists, and ethicists that review these chemotherapy orders, particularly for cisplatin, and try to use some guiding principles that we learned from COVID as well as ASCO's guidance to decide how we assign our resources. That's one option, one way we have done it.    And then in another situation that was faced by one of my GI oncology colleagues was a patient that was originally planned to go on a clinical trial where the chemotherapy backbone was FOLFOX and because we had the 5FU shortage, we could not offer that patient clinical trial enrollment. And that was a tough conversation where they had to tell them that they could not go on a clinical trial that they were looking forward to. And this then brings the next question, which is by foregoing the bolus 5FU and by the 10% reduction in the infusional 5FU, are we providing them inferior treatment? And it's a conversation that's had at a very individual level. I don't envy my colleague who had to have that conversation. It's a challenge and we try to do our best to communicate to our patients that we are trying to provide care without trying to compromise the effectiveness of treatment for them.  Dr. Vamsi Velcheti: Thank you so much both of you. And we had the same issues here at NYU in New York City as well. It appears, you know, the degree of shortage and the drugs that are in shortage has been somewhat different at different locations across the United States. But the theme has been that we are having to ration treatments for our patients. And of course, there are some tumor types where there's really no adequate substitution, for example, GU cancers. I mean, you can't really not give them cisplatin. A lot of these are situations which have curative intent and young patients. So, it's really troubling.   And I think one of the things that really came out of this is there's been a lot of push from professional societies that actually ASCO has been spearheading and some intense discussions with CMS and legislators to kind of provide more long-term fix for these things. And I think all of us have to be more engaged in those discussions with our professional societies like ASCO to kind of help promote awareness. So if you kind of think about it, these drugs are not that expensive. These are generic drugs that we've all been using for such a long time. And the fact that we can't provide these drugs for various reasons is kind of really concerning. We spend so much money on research and more expensive drugs and not being able to manufacture these drugs within the country and kind of having to rely on complex supply chains is troubling, and I hope the situation improves very soon.    So, I know both of you are at large cancer centers that enroll patients on clinical trials. Of course, these drugs, especially carboplatin, for lung cancer, especially, are like core treatments that are used in managing cancer patients with lung cancer. So how is this affecting your clinical trial accrual? Are you prioritizing patients on clinical trials for these drugs? Have you had to make any decisions to hold clinical trial accrual for certain trials? Kind of curious to hear.  Dr. Taofeek Owonikoko: Yeah, so I can maybe weigh in a little bit on that in terms of what we've had to do for patients receiving treatment as standard of care versus those going on clinical trials. As we all recognize that when a patient goes on a clinical trial, even if they are going to receive a standard-of-care regimen as part of that trial, it still has to be administered in line with the protocol. So, during the extreme period of shortage anxiety, we actually had consideration for perhaps not putting patients on trial if we're not sure that they will be able to continue to receive the protocol-mandated treatment, whether it's a control intervention or the experimental intervention.   The good thing to come out of this is at least here at UPMC, we actually did not have any instance where we had to deny a patient clinical trial participation. But there were anxious periods when we already had patients enrolled and they were scheduled to receive a platinum-containing regimen and we were not sure whether or not we were going to have adequate supply of the drug for them while on trial. I think this really raises an important consideration going forward as we come out of this current shortage. I don't by any stretch of the imagination assume that this is going to be the last one we experience, but I think the lessons learned here, we have to also carry that forward both in the design of the trial as well as in the regulatory environment surrounding clinical trial conduct, to say, should another incidence of drug shortage are to happen, how do we actually operationalize that with respect to patients on trial, whether starting or already on trial?   I think it's much more challenging when the patient is already on the trial, they've already started. It's less challenging if you just have to make a decision about somebody starting newly on the trial. But equally important is that by not allowing new patients to go on trial is denying something that potentially could be of benefit to them, albeit it is still a trial, it's not an established treatment option yet.  Dr. Janakiraman Subramanian : I completely agree with Dr. Owonikoko. Those were very key points and issues that we face as well. In terms of my patients with lung cancer, we haven't had a problem in getting them on clinical trials. Even though we have had carboplatin shortage patients who are already on treatment, they were able to get the carboplatin. For new patients, we were still able to provide them carboplatin as well. The biggest problem for clinical trials has been primarily with my GI colleagues who have to use 5FU. And there, as I said before, we are unable to give bolus 5FU and there is a 10% reduction of the infusional 5FU. So, we can't have any of these patients go on clinical trials.    And as a result, anything that has to do with 5FU has come to a screeching halt in terms of clinical trials for our patients. And I think I echo the point of Dr. Owonikoko that by no means this is the last drug shortage we're going to be dealing with and we are here today discussing this, also because this shortage has not ended. It's been ongoing. It's one of the longest drug shortages in my memory as a medical oncologist, and that's concerning. We still see that there is some improvement, but we haven't gotten past it yet.     And therefore, as we develop clinical trials and we need to have methods to address drug shortages and how we manage patient enrollment as well as how do we manage existing patients who are already on a clinical trial and, if possible, what might be their options in that situation. We may not have all the answers, but it is definitely an issue that we need to think about in the future as we develop and implement newer clinical trials for our patients.  Dr. Vamsi Velcheti: I completely agree and great points, both of you. And we've had the same issues with clinical trials at NYU Langone as well due to the shortage. It's been a challenge, and I think this is a problem that's so complex because of supply chain issues and the way the drugs are priced and incentives for manufacturing these drugs in the United States are not lucrative enough to actually onshore a lot of the production of these drugs.   I think at the end of the day, I think we have to come up with some creative, innovative, reimbursement structures for these generic chemotherapy drugs. I think this would require a very complex economic solution that perhaps ASCO and other organizations should kind of really foster an environment of innovation to kind of help facilitate onshoring some of the manufacturing of these key drugs within the United States. I think ASCO is already trying to do that, trying to collaborate with all the stakeholders to kind of address this problem is very critical, and I think all of us have to be engaged in some of the advocacy efforts that are ongoing to kind of address these drug shortages. And this is not a short-term problem.  So, Dr. Owonikoko and Dr. Subramanian, any final thoughts before we wrap up the podcast today?  Dr. Janakiraman Subramanian: So, Vamsi, you mentioned the whole complex supply chain and the fact that we rely primarily on overseas manufacturers to get these drugs that are off-patent but still a key backbone of our cancer treatment. I think those are all key issues that policymakers and leaders in the field have to keep in mind. As an institution at Inova, one of the key mechanisms that have helped us to sort of stay ahead of the shortage was to have this inventory management team that monitors the inventory out there. And in fact, the inventory management team does have access to what the inventory is in some of their main suppliers in terms of the drugs. And they also have an idea of how many patients are going through treatment, what is the weekly usage of a specific drug like carboplatin. And they try to forecast what is coming down the road and try to prepare for it.   And as we try to look for solutions, maybe a forecasting mechanism in a larger scale like either spearheaded by ASCO or by policymakers level that can, for the overall country, try to see where some of the inventory is for some of these critical drugs and try to prepare for it ahead of time, rather than wait till we hit the shortage and then try to find alternative suppliers to get the drug, which obviously doesn't happen quick enough. It takes months or even longer to catch up and get the inventory back to the level where we can comfortably take care of our patients.  I think that is something we should be advocating for that as well as the professional societies should take a handle on that and see if they can support something like that as well as letting the institutions know ahead of time what's coming might be very helpful.  Dr. Vamsi Velcheti: Yeah, very good point, Janakiraman, and I think that's a key takeaway here. I think we have to learn from other industries and try to– I mean this is not unique to healthcare by any means. I mean these chronic shortages due to supply chain issues, inventory management, there might be some learnings from other industries here that we probably should also focus on inventory management and improve supply chain logistics.   Dr. Owonikoko, any closing thoughts?   Dr. Taofeek Owonikoko: Yeah, I agree as well with all the points made by Dr. Subramanian and yourself. This is a chronic problem that requires a long-term strategy. I think it's both an economic problem as well as a regulatory problem. As we all know, part of the reason why we went through this current crisis is the regulatory decision by the FDA regarding safety of one of the manufacturers. So being proactive in terms of how these audits are conducted and giving people lead time I think will help avoid similar situations in the future.    It's an economic problem. There's a reason why a lot of the big pharma companies are not producing these drugs. And if the cost of production is such that the amount of money you get paid is enough to cover your price, I think there is an economic issue there to be addressed. That is unfortunately not within the scope of what any one of us can do individually, but as advocates in terms of the structure of incentivizing new drug versus old drug, some of these newer drugs are quite expensive, but oftentimes they are used along with standard drugs that are not as expensive. So, where do we strike that balance where we do not stifle innovation but at the same time, we don't create a perverse incentive system where everybody just wants to come up with the newest, most expensive drug and nobody is interested in really producing the backbone chemotherapy and other agents that will make those new drugs work well.   So, I think we have to pay attention. We have to advocate for our patients through our different institutions and organizations, and I hope that society as a whole that we've learned a lot of lessons from this crisis and that will help us craft some long-term strategies.   Dr. Vamsi Velcheti: Thank you both Dr. Owonikoko and Dr. Subramanian for your time today to speak with me and our listeners and for sharing your insights with us on the ASCO Daily News podcast.   Dr. Taofeek Owonikoko: Thank you.   Dr. Janakiraman Subramanian: Thank you.  Dr. Vamsi Velcheti: And thank you to our listeners for your time today. If you value the insights that you hear on ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcast. Thank you so much.  Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  ASCO Resources Related to Drug Shortages are available here.     Follow today's speakers:    Dr. Vamsidhar Velcheti    @VamsiVelcheti    Dr. Janakiraman Subramanian  @RamSubraMD  Dr. Taofeek Owonikoko  @teekayowo    Follow ASCO on social media:     @ASCO on X (formerly Twitter)    ASCO on Facebook    ASCO on LinkedIn      Disclosures:     Dr. Vamsidhar Velcheti:     Honoraria: ITeos Therapeutics    Consulting or Advisory Role: Bristol-Myers Squibb, Merck, Foundation Medicine, AstraZeneca/MedImmune, Novartis, Lilly, EMD Serono, GSK, Amgen, Elevation Oncology, Taiho Oncology, Merus    Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline      Dr. Janakiraman Subramanian:  Consulting or Advisory Role: AstraZeneca, Boehringer Ingelheim, Pfizer, Novartis, Daichi, G1 Therapeutics, Jazz Pharmaceuticals, Janssen Oncology, Lilly, Blueprint Medicines, Axcess, BeiGene, Cardinal Health, Takeda, OncoCyte  Speakers' Bureau: AstraZeneca, Boehringer Ingelheim, G1 Therapeutics, Jazz Pharmaceuticals, Janssen Oncology  Research Funding (Inst.): G1 Therapeutics, Tesaro/GSK, Novartis, Genentech, Novocure, Merck   Dr. Taofeek Owonikoko:  Stocks and Other Ownership Interests: Cambium Oncology, GenCart, Coherus Biosciences  Consulting or Advisory Role: Novartis, Celgene, Abbvie, Eisai, GI Therapeutics, Takeda, Bristol-Myers Squibb, MedImmune, BerGenBio, Lilly, Amgen, AstraZeneca, PharmaMar, Boehringer Ingelheim, EMD Serono, Xcovery, Bayer, Merck, Jazz Pharmaceuticals, Zentalis, Wells Fargo, Ipsen, Roche/Genentech, Janssen, Exelixis, BeiGene, Triptych Health Partners, Daichi, Coherus Biosciences  Speakers Bureau: Abbvie  Research Funding (Inst.): Novartis, Astellas Pharma, Bayer, Regeneron, AstraZenece/MedImmune, Abbvie, G1Therapeutics, Bristol-Myers Squibb, United Therapeutics, Amgen, Loxo/Lilly, Fujifilm, Pfizer, Aeglea Biotherapeutics, Incyte, Merck, Oncorus, Ispen, GlaxoSmithKline, Calithera Biosciences, Eisai, WindMIL, Turning Point Therapeutics, Roche/Genentech, Mersana, Meryx, Boehringer Ingelheim  Patents, Royalties, Other Intellectual Property (Inst.):   Overcoming Acquired Resistance to Chemotherapy Treatments Through Suppression of STAT3  Selective Chemotherapy Treatments and Diagnostic Methods Related Thereto  DR4 Modulation and Its Implications in EGFR-Target Cancer Therapy Ref: 18089 PROV (CSP) United States Patent Application No. 62/670,210 June 26, 2018 (Co-Inventor)  Soluble FAS ligand as a biomarker of recurrence in thyroid cancer; provisional patent 61/727,519 (Inventor)  Other Relationship: Roche/Genentech, EMD Serono, Novartis  Uncompensated Relationships: Reflexion Medical           

Successful Collaborators with Paul McEnroe, co-inventor of the Bar Code.Become a supporter of this podcast: https://www.spreaker.com/podcast/success-made-to-last-legends--4302039/support.

Inventor of Telegraph and Co-Inventor of Morse Code --- Send in a voice message: https://podcasters.spotify.com/pod/show/rocky-seale7/message

The Personal Computer Show Wednesday March 29th 2023 PRN.live Streaming on the Internet 6:00 PM Eastern Time IN THE NEWS  Gordon Moore, Intel Co-Founder Passed Away at Age 94  Turing Award Won by Bob Metcalf, Co-Inventor of Ethernet Technology  Non Disparagement Clauses Disallowed In Severance Agreements  FTC Ban Non Compete Clauses  Cable and Satellite Providers Required to Display True Price of Service  Pinduoduo with Hundreds of Million Users Accused of Distributing Malware  Work from Home Employees Fallen to 16.4% in 2022 ITPro Series with Benjamin Rockwell  2 Factor Authentication in Our Lives From the Tech Corner  Listening to Over 30,000 Radio Stations Around the World  World Backup Day – March 31, 2023  Judge Ruled Group of Book Publishers Over Internet Archive's Online Library  Artificial Intelligence vs Ancient Sport of GO Technology Chatter with Benjamin Rockwell and Marty Winston  Electric Vehicle Insights.

OVERVIEW: "Fortune favors the bold." – Latin Proverb Jason A. Duprat, Entrepreneur, Healthcare Practitioner, and Host of the Healthcare Entrepreneur Academy podcast, sits down with Joey Ferry, Nurse Entrepreneur, Co-Founder of Frontier Innovations Inc., and Co-Inventor of the Award-Winning SafeSeizure Pad. In this episode, we hear the story of how two innovative minds came together to revolutionize Healthcare through their Entrepreneurial vision. From the challenges they've overcome to the solutions they create, Joey's innovation paved the path toward their "good fortune."   3 KEY POINTS: You'll get to where you need to be, but take it one step at a time. To start a business, know what you're good at and talk to people about that. Sales expertise boils down to repetition.   EPISODE HIGHLIGHTS: Joey has a strong passion for entrepreneurship, even as a child. He once veered away from his Entrepreneurial passion and pursued Nursing for its financial security. Later, upon meeting his now business partner, Taofiki, he realized he could pursue both Entrepreneurship and Healthcare without sacrificing either. They discovered they had the same entrepreneurial passion and decided to work together towards a common goal. Joey creates products for ether two reasons: Solving a problem and providing convenience, even without much financial gain Creating a viable and potential business opportunity When creating prototypes, it doesn't have to be the final product. You simply want to test, feel, and play with it. Be okay with accepting the solution that might look different than when you first started. Joey and Taofiki are registered nurses who invented a new way to pad bed rails for patients on seizure precautions in the hospital setting. They source their materials from Alibaba from a manufacturer who can make the products in their desired dimensions. Once their business got off the ground, the product's revenue fueled itself. They once had struggles with their inventory. Fortunately, they won the 2020 Innovation Award and received $50,000, wherein half was directly invested in solving their inventory concerns. Joey recommends Wave Apps, a free software for new businesses for handling invoices, adding various products, adding customers, etc. Joey recommends upgrading to a paid tool when your business begins to scale. Sales expertise boils down to repetition. If you're not too experienced in sales yet, you might feel as if you're "bothering" people. Joey and Taofiki maintain a solid personal connection with their customers by signing emails with their names and including their contact numbers. To know more about SafeSeizure, visit their website at https://www.safeseizure.com/ Feel free to connect with Joey Ferry and LinkedIn.   TWEETABLE QUOTES: "You'll get there, but a lot of folks will give up early because they're looking at Z rather than looking at A, B, and C. Focus on the next couple of steps and don't worry about X, Y, and Z yet." – Joey Ferry "For anybody looking to start a business, know what you know, know where you shine, what you're good at, and where you thrive, and talk to people that want that." – Joey Ferry   CONNECT WITH JASON DUPRAT LinkedIn | Facebook | Instagram | Youtube Email: support@jasonduprat.com Join our Facebook group: https://jasonduprat.com/group    RESOURCES: Want to become a Ketamine Therapy provider? Enroll NOW in The Ketamine Academy course: https://ketamineacademy.com/presentation Sign up for one of our free business start-up Masterclasses by heading over to https://jasonduprat.com/freemasterclass  Have a healthcare business question? Want to request a podcast topic? Text me at 407-972-0084 and I'll add you to my contacts. Occasionally, I'll share important announcements and answer your questions as well. I'm excited to connect with you! Do you enjoy our podcast? Leave a rating and review: https://lovethepodcast.com/hea  Don't want to miss an episode? Subscribe and follow: https://followthepodcast.com/hea   RELATED EPISODES: #284: BE OBSESSED OR BE AVERAGE: AN INNOVATOR'S GUIDE TO BUILDING A VIRTUAL CARE COMPANY WITH GUY FRIEDMAN #219: TRAVIS HORNSBY: TRUST IN YOUR BIGGEST INVESTMENT – YOURSELF #279: WHY IS IT SO IMPORTANT TO INVEST IN YOURSELF NOW MORE THAN EVER? #HealthcareEntrepreneurAcademy #healthcare #HealthcareBoss #entrepreneur #entrepreneurship #podcast #businessgrowth #teamgrowth #digitalbusiness

Walking the aisles of the Fancy Food Show in Las Vegas earlier this year, a gentleman stuck a sparkling wine glass in my face and said “Do you like wine?” I responded, “Is this a joke?” He went on to tell me that this was an Italian non-alcoholic sparkling wine that he and his wife had created. I have tasted many non-alcoholic wines and they all suck. With trepidation, I tasted it. This was a decent wine. I was shocked and impressed. Come on my show I said…turns out he is in So Cal and I met Marco Marano. 

Jeff Kutas is an innovator at heart.  Co-Inventor & Founder of MB Sentinel™ Enterprises the maker of top quality Mailbox & Box Sentinel Parcel Safes, 2021 Best Product Texas   2022 Texas ⭐️ Award Finalist 2022 Architecture Masterprize WinnerJeff saw an opportunity to make life easier for consumers + leaned into his knowledge expertise + friendships to bring it fruition.  MB Sentinel is a magical product that safeguards our door-to-door deliveries, from climate, package pirates + other challenges.  This conversation is wonderful. Jeff speaks about how after decades in the retail space, he decided to pivot (when many others could have stuck it out) to the next path of his business life- knowing that not making a decision is still a decision + how that enabled him + continues to be a pillar in his life.Jeff vividly talks about how he actually cares for the people in his world, reminds us that we can't do it alone + we get emotional about what it really means to give back + acknowledge the things that are bigger than you + I.Click on link about MB Sentinel or Box GobblerJeff Kutas can be reached directly hereOrder your MB Sentinel hereConnect with JonathanKeynote speaker, Consultant, Trainer + Performance Coach: www.jonathancinelli.comAuthor:  Kick Your Ego aside and Put People FirstEducation: ProjectBitesIG@jonathanacinellifacebook.com/jonathancinellipmSupport the showAppreciate the content we provide?Buy a coffee as a way of supporting the production of the showhttps://www.buymeacoffee.com/jcinelli

Part 2 of 2Predictive NPS - How Loyalty Measurement is Changing with Rob MarkeyA powerful, insightful, revealing interview so packed with gems that I had to break it into two parts!Rob Markey is the Co-Inventor of the Net Promoter System and the Co-Author of The Ultimate Question 2.0.In Part 2 (this episode):We discuss:Rob's definition of customer experienceThe impact of digital transformation on CXWhy and how NPS will still play a role despite the emergence of technologyThe evolution of NPS in a digital worldIs it moral and ethical to treat every customer the same? (hint - his answer may surprise you!)Rob Markey BioHas led dozens of successful customer-centric transformations at large, global companies​Creator of Bain's approach to customer-centricity​ Introduced Earned Growth through Customer Value Management in “Are You Undervaluing Your Customers,” Harvard Business Review, Jan-Feb 2020​ Co-inventor of the Net Promoter System; co-author The Ultimate Question 2.0; Leader of Bain's NPS Loyalty Forum​Founder of Bain's Customer Strategy and Marketing practice​30+ years at Bain​MBA, Harvard; BA, Brown​ Ran 7 marathons and aspires to complete all the world majors by 2024And by the way, happens to host his own podcast, The Net Promoter System PodcastSubscribe to The Delighted Customer Podcast so you don't miss an episode: https://www.empoweredcx.com/podcast Subscribe to The Delighted Customer Newsletter for practical tips and insights: https://www.empoweredcx.com/delightedcustomersnewsletter

Rob Markey on the Delighted Customers Podcast Part 1 of 2What would you expect from one of the top CX thought leaders in the world?A powerful, insightful, revealing interview so packed with gems that I had to break it into two parts!Rob Markey is the Co-Inventor of the Net Promoter System and the Co-Author of The Ultimate Question 2.0.In Part 1 (this episode):We discuss:Loyalty levers to pull in a down economyHow loyalty leaders can excel in a recessionWhy Rob initially rejected a single question to measure customer loyalty?This misinterpretation of Net Promoter ScoreWhy that one question was selected as the right question to measure customer loyaltyRob Markey BioHas led dozens of successful customer-centric transformations at large, global companies​Creator of Bain's approach to customer-centricity​ Introduced Earned Growth through Customer Value Management in “Are You Undervaluing Your Customers,” Harvard Business Review, Jan-Feb 2020​ Co-inventor of the Net Promoter System; co-author The Ultimate Question 2.0; Leader of Bain's NPS Loyalty Forum​Founder of Bain's Customer Strategy and Marketing practice​30+ years at Bain​MBA, Harvard; BA, Brown​ Ran 7 marathons and aspires to complete all the world majors by 2024And by the way, happens to host his own podcast, The Net Promoter System Podcast

Scott Stornetta is a Grandfather, Teacher, Investor and scientific researcher – and an invention he did 30 years ago totally revolutionizes the world of tech today. In 1991, he and Stuart Haber, published the whitepaper "How to Time-Stamp a Digital Document”. This paper, in fact, could be described as the invention of blockchain. In 1992 this paper won the Discover Award for Computer Software; it's considered to be one of the most important papers in the development of cryptocurrencies as we know it today.Tune into this fascinating conversation as we explore inventing blockchain by proving its impossibility, the current state of trust and blockchain's role in fixing it, stakeholders in mass adoption of timestamps and Web3 – and Self-Sovereign Identity (SSI) and how to get there.For full show notes visit https://thetrustedweb.org/podcast/.

This podcast was recorded in early November, on the sidelines of the Singapore Fintech Festival 2022. It was fitting in the spirit of the event to have Stuart Haber join Kopi Time. Dr Haber, along with Scott Stornetta, co-invented the blockchain technique in 1990, which was later adopted by Satoshi Nakamoto as the basic mechanism for data integrity in Bitcoin. We begin the conversation travelling back over three decades, to understand the problem and motivation that drove Haber and Stornetta toward the blockchain. It is clear even as young coders and crypographers, their ambition was high and their goal was to have transformative and lasting impact on the way civilisation's records are stored. We then talk about the seminal moment in 2008, when the Satoshi white paper came out, and Dr Haber's take on it then (and now). We tackle the questions of a crypto bubble, Bitcoin's adverse environmental impact (and possible solutions around it), proliferation of tech solutions looking for a problem, and the applications that appeal to him. Dr. Haber talks about his current research, and takes on my question on the potential impact of quantum computing on cryptograhy-based record authentication. A brilliant mind with outstanding insights.See omnystudio.com/listener for privacy information.

It's time once again for for us to kick back with our sketchbooks and coffee cups, as we Interview Jeff Kutas, Co-Inventor and Founder of MB Sentinel Enterprises, Entrepreneur, and Published Author. On this episode, we talk about his company - which focuses on designing parcel safes and mailboxes. Additionally, he gives advice as a CEO, and tips and tricks for young designers, and those interested in potentially kicking off their own businesses. The blog is located at architecturecoffeeandink.com which also has the complete link of all my sources, previous episodes, and old blog posts posted a few hours after each episode comes out. You can email me at architecturecoffeeandink@gmail.com, or head over to the Insta, @architecturecoffeeandink,as well as the TikTok, @architecturecoffeeandink. MB Sentinel Enterprises can be found at https://mbsentinel.com/.

Know Stroke Podcast -S4E3-Henry Hoffman On this episode we were joined by Henry Hoffman,MS,OTR/L co-inventor and co-founder of Saebo, Inc. We were introduced to Henry through Dr. Carolyn Brown, a previous guest of the podcast in season one. Saebo, Inc. is a medical device company primarily engaged in the discovery, development and commercialization of affordable and novel clinical solutions designed to improve mobility and function in individuals suffering from neurological and orthopedic conditions. With a vast network of Saebo-trained clinicians spanning six continents, Saebo has helped over 100,000 clients around the globe achieve a new level of independence. About our Guest: Henry graduated from D'Youville College in Buffalo, NY in 1997 with a Masters degree in occupational therapy. Since graduation, he has worked in a variety of settings including home health, acute, sub-acute, and outpatient rehab. Prior to leaving Burke Rehabilitation Hospital in New York, he worked as a clinical specialist in orthopedic medicine and manual therapy of the upper quadrant. Henry left Burke in the fall of 2002 to co-launch Saebo. This was a great discussion and as co-hosts we share a common mission with Henry to continue to dispel the believe that stroke recovery has an end when a “plateau” is reached. Listen in to learn how Henry and his team are on a mission to offer new affordable treatment options that deliver tangible results, and offer hope and support for continued recovery and improved function. Learn more about Saebo's mission and connect with Henry here. In the News mentions:  Neurology Live Show Credits: Music Credit and Podcast Production by Jake Dansereau, connect at JAKEEZo on Soundcloud @user-257386777 Be sure to give the show a like and share, +follow and connect with us on social or contact us to be a guest on the  Know Stroke Podcast

Guest BioArlen is the co-Inventor of MQTT – The leading protocol for IoT( Internet of Things), specializing in Industrial Internet of Things (IIoT) and SCADA software solutions. With over 40 years of experience in the SCADA & IIoT industry, Arlen has broad experience covering the design and manufacture of embedded computer systems to complete SCADA system infrastructure implementations for many companies. A leading expert on MQTT involved in many activities including published articles and speaking engagements on educating the use of publish/subscribe methodologies for operational technologies and digital transformation. Main Discussion Points How and why MQTT was invented The adoption of MQTT as a lightweight and modern protocol How IIoT has forced us to rethink many of the legacy ways we've been working on automation and manufacturing. Theme: IIoTManufacturing Hub Episode 67.Big thank you to Phoenix Contact for sponsoring this theme and for your continued support of the community.Recommended Materials- The C Programming LanguageConnect with Us Arlen Nipper Vlad Romanov Dave Griffith Manufacturing Hub Let Us Know What You ThinkIf you enjoyed the show, it would mean the world to us if you could leave us a review: https://podcasts.apple.com/us/podcast/manufacturing-hub/id1546805573#automation #manufacturing #IIoT #MQTT

In today's episode, John speaks with Dag Kittlaus, Co-Inventor of Siri and current Co-Founder/CEO at Riva Health.  They Discuss What Did Steve Jobs Originally Want to Call Siri? What is the Biggest Healthcare issue in the world? How many people that are prescribed blood pressure meds don't fill their prescription? How did Siri help catch a Killer? Enjoy! To make sure you never miss an episode of The High EQ Market podcast, subscribe on Apple Podcasts, Spotify, and the website. Listening on a desktop & can't see the links? Just search for The High EQ Marketer in your favorite podcast player.

Cedar Anderson the Co-Inventor, CEO & Co-Founder of Flow Hive and the Flow Hive technology that has been hailed as the biggest innovation in beekeeping since 1852 joins Enterprise Radio. The post Flow Hive, the biggest innovation in beekeeping since 1852 appeared first on Enterprise Podcast Network - EPN.

Yahoo Finance Tech Editor Dan Howley speaks with iPhone & iPod co-inventor Tony Fadell about his new book 'Build' as well as the future of technology. See acast.com/privacy for privacy and opt-out information.

Caroline's Cart and transportation for special needs individuals while shopping in store Drew Ann Long, Co-Founder of Caroline's Cause and Co-Inventor of Caroline's Cart with Hannah Burt Wilson _ Alabama Care is partially supported by http://www.ACDD.org The views expressed are not necessarily the views of these organizations.

Felix, Felix, Markus und Ingo sind wieder dabei und haben diesmal das Thema Audioabspielserver. Blast from the Past Mailu via Thomas SOGo z-push active sync Toter der Woche moovel zum 31.3 A patch to deprecate #reiserfs David Boggs, Co-Inventor of Ethernet, Dies at 71 Untoter der Woche Solaris 11.4 CBE How are OpenIndiana and illumos related? Fujitsu kündigt das Mainframe-Aus an – und schmiedet neue Mainframe-Pläne News Linux-Kernel-Lücke erlaubt Schreibzugriff mit Root-Rechten The Dirty Pipe Vulnerability 10 years Raspberry Pi SailfishOS / Jolla will russische Investoren loswerden radiotux sendung Frankreichs Aktionsplan für Open Source prototype fund nextcloud podcast NVIDIA confirms data was stolen in recent cyberattack fuck you nvidia Execution and Static Analysis Support for MSVC on Compiler Explorer Online Disassembler Ntfs2btrfs Themen Personal Audio Server Protokolle (DAAP, Subsonic, UPnp, ) navidrome Ampache Clients DSub iSub (iOS) Substreamer (iOS) Plex MPD ympd Die Phoniebox toniebox-audio-match HiFiBerry Mimimi der Woche Plantuml Go Open Source wifi + firetv Lesefoo We’ve Been Here Since the Beginning Contributing to the FreeBSD Ports Collection Algorithms for Modern Hardware “There are only two hard things in Computer Science: cache invalidation and naming things.” Modern Unix less -R Why you shouldn’t invoke setup.py directly sprawl trilogy start with book 0! How To Read Neuromancer (William Gibson) William Gibson - Neuromancer: Sprawl Trilogy. Quick Review William Gibson - Cyberpunk - BBC Late Show © 1991 How to configure xdg-open Talks Law of Demeter: A Practical Guide to Loose Coupling - Kris Jusiak - CppCon 2021 CppCon 2017: Carl Cook “When a Microsecond Is an Eternity: High Performance Trading Systems in C++” Keynote: C++’s Superpower - Matt Godbolt - CPPP 2021 Why Isn’t Functional Programming the Norm? – Richard Feldman Why Are there Holes in the James Webb Sunshield? Picks git-interpret-trailers - Add or parse structured information in commit messages Google slides is actually hilarious strut.io Hyundai’s Strange Cold-Weather UI Bug: Digital Dashboard Rotates, Flips Display fbtft fb_st7789v.c driver Unredacter ITX-3588J HoneyComb LX2 750$ Mike Tyson Mysteries download in der Schweiz Bei Ebay kaufen in Deutschland

The Personal Computer Show Wednesday March 2, 2022 PRN.live Streaming on the Internet 6:00 PM Eastern Time IN THE NEWS o David Boggs, Co-Inventor of Ethernet o Restrictions on High Tech Exports to Russia o Russian Invasion Fallout and the International Space Station o Ukraine's Supply Chain Role in Global Semiconductor Production o Computer Chip Industry Begins Halting Deliveries to Russia o ARM China Seizes IP, Relaunch as Independent Company IT Pro Series with Benjamin Rockwell o What is Software Volume Licensing From The Tech Corner o 3 Months and 700 Steps to Produce a Computer Chip o Intel High Performance Computer - 1 exaFLOPS Ponte Vecchio Technology Chatter with Benjamin Rockwell and Marty Winston o Subaru Accident Leads to New Car Technology

In this episode of Beltway Broadcast, your Metro DC Chapter of ATD hosts Brian Washburn. Brian is the Co-Inventor of Soap Box and Co-Founder and CEO of Endurance Learning. He is an instructional designer, podcaster, speaker, and the author of What's Your Formula? Combine Learning Elements For Impactful Training and multiple articles for TD Magazine. In this episode, Brian describes the Presenter Quadrant, discusses presenting styles, and shares how presenters can focus on the necessary strategies to enhance their practice.     If you'd like to learn more about Brian, checkout his LinkedIn profile or visit his company's website.   For more info about the Metro DC Chapter of ATD, visit DCATD.org.  Episode Credits: Series Announcer: Julie Waters Hosts: Christina Eanes, Stephanie Hubka, Laëtitia Gnago, and Halyna Hodges

Dr. Madhavi Gavini is the Co-Founder, Co-Inventor, and CEO of Droplette, a technology company revolutionizing skincare with a breakthrough device of the same name. Regarded as the latest revolutionary skincare gadget, Droplette is a transdermal delivery tool that delivers active ingredients under the skin. Madhavi is also the President and Co-Founder of Novopyxis, an award-winning biotechnology company dedicated to developing therapeutics and medical devices. Dr. Madhavi Gavini joins me today to discuss revolutionizing and democratizing skincare and beauty. She explains how Droplette solves the inefficiencies of topical drug application and describes how it avoids the side effects of common skin treatments such as peels. She shares what inspired the creation of Droplette and her advice for women seeking other women co-founders. She also highlights the foundations young people should build if they are to embark on entrepreneurship and science and describes how trailblazing women continue to impact women in STEM today. “The skin is the largest organ in your body and tends to be the last one to receive nutrients and support. It's not just about beauty; it's about the health and wellness of your skin.” - Madhavi Gavini This week on Girls in Tech: The genesis of Droplette and how Madhavi met her co-founder Droplette's medical, skincare, and cosmetic applications What Epidermolysis Bullosa (BD) is and how it inspired Madhavi and her co-founder to create a transdermal device How Droplette shifted from initially treating EB to skincare Democratizing beauty and skincare and how Droplette adapted its marketing amid COVID-19 Why Droplette is an effective solution for drug delivery Other dermatological issues Madhavi is invested in Madhavi's advice on finding a woman co-founder The impact of trailblazer women in STEM Research and Development: other tech Madhavi and Droplette are interested in working with What it feels like to invent a novel technology that improves peoples' lives Connect with Madhavi Gavini: Droplette Droplette on LinkedIn Droplette on Instagram Droplette on Facebook Droplette on Twitter Madhavi Gavini on LinkedIn Inspiring Girls in Tech...One Conversation at a Time Thanks for tuning into this week's episode of Girls in Tech. If you enjoyed this episode, please subscribe and leave a review wherever you get your podcasts. Apple Podcasts | TuneIn | GooglePlay | Stitcher | Spotify | iHeartRadio Be sure to share your favorite episodes on social media to help us reach more listeners, like you. Join us on Facebook, Twitter, Instagram, and LinkedIn. For more exclusive content and information, visit our website.

This week on The Encrypted Economy, we are joined again by Dan Bogdanov, Director of the Information Security Institute at Cybernetica and the Co-Inventor of Sharemind. With a Ph.D. in Informatics and a master's degree in Computer Science, Dan shares his expertise on digitization initiatives and privacy preservation. Be sure to subscribe to The Encrypted Economy for more perspective on countries leading in the adoption of privacy-enhancing tools and other innovative technologies. Topics Covered:· Introduction· How Do Privacy Enhancing Technologies Enable Outsourcing Functions?· Discussing Functional Encryption · What Differentiates Sharemind?· Using MPC with Federated Learning Frameworks· Sharemind's Vision for the Future· Addressing Privacy Washing· The Digital Identity EvolutionResource List:· Dan's LinkedIn· Dan Bogdanov Twitter · Cybernetica· Sharemind· Homomorphic Encryption· Multi-Party Computation· Zero-Knowledge Proofs· Federated Learning· IOS 15 ID StorageFollow The Encrypted Economy on your favorite platforms! Twitter LinkedIn Instagram Facebook      

This week on The Encrypted Economy, my guest is Dan Bogdanov, Director of the Information Security Institute at Cybernetica and the Co-Inventor of Sharemind. With a Ph.D. in Informatics and a master's degree in Computer Science, Dan shares his expertise on digitization initiatives and privacy preservation. Be sure to subscribe to The Encrypted Economy for more perspective on countries leading in the adoption of e-governance tools and other innovative technologies. Topics Covered:·       Introduction·       Dan's Background·       Why Does Estonia Take the Lead in Digitalization?·       E-Residency and E-Voting in Estonia·       Forming a Company in Estonia with E-Governance·       Privacy-Enhancing Technologies in E-Voting Systems·       Discussing the Partnership Between Cybernetica and Estonia·       Is Homomorphic Encryption a Solution for Privacy Preservation·       Estonia's Digital Currency Initiatives·       OutroResource List:·       Dan's LinkedIn·       Dan Bogdanov Twitter ·       Cybernetica·       Sharemind·       Tom Attema Episode·       Estonia's E-Governance  ·       Estonia Digital Currency R&D·       Cybernetica partners with PwC Middle East ·       Cybernetica Smartphone-Based ID authentication ·       University of Tartu and Cybernetica Cooperate to Study Quantum-Safe Cryptography ·       Panel Discussion: Lessons on How to Make Data Run, Not People  Follow The Encrypted Economy on your favorite platforms! Twitter LinkedIn Instagram Facebook      

Dr. Madhavi Gavini is the Co-Founder, Co-Inventor, and CEO of Droplette, a technology company revolutionizing skincare with a breakthrough device of the same name. Regarded as the latest revolutionary skincare gadget, Droplette is a transdermal delivery tool that delivers active ingredients under the skin. Madhavi is also the President and Co-Founder of Novopyxis, an award-winning biotechnology company dedicated to developing therapeutics and medical devices. Madhavi joins me today to discuss revolutionizing and democratizing skincare and beauty. She explains how Droplette solves the inefficiencies of topical drug application and describes how it avoids the side effects of common skin treatments such as peels. She shares what inspired the creation of Droplette and her advice for women seeking other women co-founders. She also highlights the foundations young people should build if they are to embark on entrepreneurship and science and describes how trailblazing women continue to impact women in STEM today. “The skin is the largest organ in your body and tends to be the last one to receive nutrients and support. It's not just about beauty; it's about the health and wellness of your skin.” - Madhavi Gavini This week on Girls in Tech: The genesis of Droplette and how Madhavi met her co-founder Droplette's medical, skincare, and cosmetic applications What Epidermolysis Bullosa (BD) is and how it inspired Madhavi and her co-founder to create a transdermal device How Droplette shifted from initially treating EB to skincare Democratizing beauty and skincare and how Droplette adapted its marketing amid COVID-19 Why Droplette is an effective solution for drug delivery Other dermatological issues Madhavi is invested in Madhavi's advice on finding a woman co-founder The impact of trailblazer women in STEM Research and Development: other tech Madhavi and Droplette are interested in working with What it feels like to invent a novel technology that improves peoples' lives Connect with Madhavi Gavini: Droplette Droplette on LinkedIn Droplette on Instagram Droplette on Facebook Droplette on Twitter Madhavi Gavini on LinkedIn Inspiring Girls in Tech...One Conversation at a Time Thanks for tuning into this week's episode of Girls in Tech. If you enjoyed this episode, please subscribe and leave a review wherever you get your podcasts. Apple Podcasts | TuneIn | GooglePlay | Stitcher | Spotify | iHeartRadio Be sure to share your favorite episodes on social media to help us reach more listeners, like you. Join us on Facebook, Twitter, Instagram, and LinkedIn. For more exclusive content and information, visit our website.

Dr. Richard Schatz is research director of cardiovascular interventions at the Scripps Heart, Lung, and Vascular Center and director of gene and stem cell therapy. His work in coronary stents launched a revolution in the treatment of coronary artery disease; over 2 million stents are placed each year. His work has had an immeasurable impact on prolonging life and reducing healthcare costs.This episode covers a cardiologist's perspective on the carnivore and low-carb diets, how the role of randomized controlled trials has changed over time, what to do to stay heart healthy.We also discuss advice for being an inventor. This includes the importance of being first to file, building a daily inventing habit, and knowing the basics of patent law. Finally, we discuss the emotional impact of having influenced 100+ million people, why his design worked, and what it was like to engage with world leaders like Lee Kuan Yew and Mother Theresa. Help The Louis and Kyle Show:If you enjoyed this episode, please share it with a friend!If you want to reach out to us, please do so on Twitter: https://twitter.com/LouisKyleShowEmail us: LouisandKyleShow@gmail.com

Dr. Chris Cetta is a board-certified orthodontist practicing with Blue Wave Orthodontics in Florida. He received his undergraduate degree from Wake Forest University in North Carolina and graduated from Rutgers School of Dental Medicine in New Jersey. Prior to specializing in orthodontics at Jacksonville University in Florida, Dr. Cetta was a practicing general and cosmetic dentist for several years. Dr. Chris Cetta is the co-inventor of Precision Aligner Buttons™ by DynaFlex. He is also the host of the Illuminate Orthodontic podcast which focuses on innovators and inventors in the profession. He also plays bass guitar for two rock bands, including the all-orthodontist group Relapse. In this episode… One common mistake many inventors make when they have a great idea is that they start making a product prototype without thinking through its execution and without considering whether to patent it or not. See, having a great idea is not good enough because an idea is only as good as the force that propels it to become a fruitful and realized endeavor. After coming up with his idea for aligner buttons, Dr. Chris Cetta knew he had a lot more to do and he continued to work hard into perfecting his invention. He not only got a patent for his product, he also took it to market and he worked on helping other orthodontists and inventors who were bound to go through the same process. In this episode of In Your Face podcast, Craig Weiss and Blair Feldman talk to the inventor of the Precision Aligner Buttons, Dr. Chris Cetta, about how he created the product, the challenges he faced in the process, and why he decided to patent the product. He also talks about his podcast and the segment of orthodontist he wishes to represent and how the COVID-19 pandemic is likely to affect the orthodontic and dental industry. Stay tuned.

Join the conversation by jumping into The Video Insiders LinkedIn Group. If you would like to be a guest on the show, send an email to thevideoinsiders@beamr.com For more podcast episodes, click here. Learn more about Beamr's technology. Today's guest: Tamar Shoham.

This amazing story chronicles Mike Muhney's journey from a $100,000 angel investment to selling the first CRM (Customer Relationship Management) software for 40 Million Dollars. Packed with important business lessons Mike gleaned from being a sales person at IBM to negotiating strategies, the importance of relationships, and the value of following your dreams, this 3 times the normal length episode takes you on a fascinating ride from a great storyteller.  Get A Company of Owners, Beached Whale, Whiteboard, and The Sink here: http://goo.gl/zggRqd   www.DarenMartin.com  http://viporbit.com/ https://www.amazon.com/Whos-Your-Orbit-Facebook-Relationships/dp/0983041504/ref=sr_1_1?ie=UTF8&qid=1496598079&sr=8-1&keywords=mike+muhney

In our pilot episode of The Webby Podcast, Webby Awards Executive Director David-Michel Davies sits down with the Co-Inventor of the Internet and Chief Internet Evangelist for Google, Vint Cerf. They talk about the early days of computing, Al Gore, and security concerns in 2017.Follow us everywhere @ TheWebbyAwardsand keep up with David-Michel @ dmdlikesProducer: Ben WagnerEditorial Supervisor: Nicole FerraroMusic: "Straight West" by Kasket Club, courtesy of Audiosocket Hosted on Acast. See acast.com/privacy for more information.